Literature DB >> 11926130

Recent developments in peptide-based cancer therapeutics.

Anil Sehgal1.   

Abstract

Peptides make up only a fraction of therapeutically beneficial pharmaceutical molecules that are either in clinical testing or in the market. Despite the initially low number and impact of peptides on therapeutics, their potential has just intensified with new developments in modifications, stability, delivery and preclinical success. With the completion of the human genome sequence and developments in the proteomics field, peptides are emerging as important molecules for cancer therapy. Several peptides with exciting preclinical results have now entered into clinical trial for the treatment of human cancers. In this review, some of the recent advances in peptide-based cancer therapeutics will be discussed.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11926130

Source DB:  PubMed          Journal:  Curr Opin Drug Discov Devel        ISSN: 1367-6733


  4 in total

Review 1.  Phage display in molecular imaging and diagnosis of cancer.

Authors:  Susan L Deutscher
Journal:  Chem Rev       Date:  2010-05-12       Impact factor: 60.622

2.  Template-constrained macrocyclic peptides prepared from native, unprotected precursors.

Authors:  Kenneth V Lawson; Tristan E Rose; Patrick G Harran
Journal:  Proc Natl Acad Sci U S A       Date:  2013-09-16       Impact factor: 11.205

3.  Inhibition of Epstein-Barr virus-induced growth proliferation by a nuclear antigen EBNA2-TAT peptide.

Authors:  Christopher J Farrell; Jae Myun Lee; Eui-Cheol Shin; Marek Cebrat; Philip A Cole; S Diane Hayward
Journal:  Proc Natl Acad Sci U S A       Date:  2004-03-19       Impact factor: 11.205

4.  Soluble Frizzled-7 receptor inhibits Wnt signaling and sensitizes hepatocellular carcinoma cells towards doxorubicin.

Authors:  Wei Wei; Mei-Sze Chua; Susan Grepper; Samuel K So
Journal:  Mol Cancer       Date:  2011-02-11       Impact factor: 27.401

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.